Glp-1 receptor agonists: effects on cardiovascular risk reduction
Cardiovascular Therapeutics, 07/31/2012
Lorber D – This review examines CV–associated effects of liraglutide and exenatide in animal models and clinical trials with patients with T2DM. Studies support the effectiveness of GLP–1 RAs in reducing hyperglycemia. Further, GLP–1 RAs represent a significant advance in T2DM treatment because they uniquely affect a broad array of CV risk factors through significant weight and systolic blood pressure reduction, improved lipid levels, and possibly, as shown in in vitro studies and animal models, through direct effects on cardiac myocytes and endothelium.